SynthesisVaccine2022
The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.
Synthesis in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Global childhood diarrhoea prevalence and its determinants: a systematic meta-analytic assessment, 1985-2024.EBioMedicine · 2025Pooled it
- Etiology-specific incidence and mortality of diarrheal diseases in the African region: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial.The Lancet. Infectious diseases · 2022Trial
- Pathogen-focused metagenomic analysis reveals predominance of human rotavirus genotypes G3 and G12 in Zambian pediatric diarrhea cases.Scientific reports · 2025Article
- Review
- Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.Human vaccines & immunotherapeutics · 2024Article
- Driving forces of continuing evolution of rotaviruses.World journal of virology · 2024Review
- Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.Vaccine · 2024Article
- Correlates of immune protection against human rotaviruses: natural infection and vaccination.Archives of virology · 2024Review
- Rotavirus in Water Environments: A Systematic Review and Meta-Analysis.Environmental health insights · 2024Review
- Rotavirus A during the COVID-19 Pandemic in Brazil, 2020-2022: Emergence of G6P[8] Genotype.Viruses · 2023Article
- Social and Environmental Determinants of Diarrheal Diseases among Children under Five Years in Epworth Township, Harare.Children (Basel, Switzerland) · 2023Article
- Prevalence, Clinical Severity, and Seasonality of Adenovirus 40/41, Astrovirus, Sapovirus, and Rotavirus Among Young Children With Moderate-to-Severe Diarrhea: Results From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa.Vaccines · 2023Article
- Gastrointestinal Infection in South African Children under the Age of 5 years: A Mini Review.Gastroenterology research and practice · 2023Review
- Genome analyses of species A rotavirus isolated from various mammalian hosts in Northern Ireland during 2013-2016.Virus evolution · 2023Article
- Comparative whole genome analysis reveals re-emergence of human Wa-like and DS-1-like G3 rotaviruses after Rotarix vaccine introduction in Malawi.Virus evolution · 2023Article
- Systematic review of the effect of additional doses of oral rotavirus vaccine on immunogenicity and reduction in diarrhoeal disease among young children.EClinicalMedicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 4 countries.
Funding
Abstract
Rotavirus remains a leading cause of diarrhoeal morbidity and mortality in young children and rotavirus vaccines are critical for reducing global disease burden. This report addresses the performance of rotavirus vaccines in countries with high child mortality. We performed a sensitivity analysis as part of a systematic review on rotavirus vaccines to inform development of World Health Organization vaccine recommendations. The efficacy of four prequalified vaccines against severe rotavirus gastroenteritis was similar across high mortality settings in Asia and Africa. Within the first year following vaccination, vaccine efficacy for the four vaccines ranged from 48% to 57% while in the second year, efficacy ranged from 29% to 54%. The four vaccines showed no increase in intussusception risk in these settings. All four vaccines appear to prevent significant numbers of severe rotavirus gastroenteritis episodes with no measurable increase in intussusception risk in high mortality settings in Africa and Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.